The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CAcTUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma.
 
Rebecca Lee
Speakers' Bureau - AstraZeneca
Research Funding - Bristol-Myers Squibb (Inst)
 
Dominic G. Rothwell
No Relationships to Disclose
 
Shien Chow
No Relationships to Disclose
 
Heather May Shaw
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Genzyme; MSD; Novartis
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Sanofi
Research Funding - Genmab (Inst); Idera (Inst); Iovance Biotherapeutics (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genmab; Idera; Iovance Biotherapeutics; MSD; Novartis; Roche
 
Samra Turajlic
Consulting or Advisory Role - Pfizer/EMD Serono
Speakers' Bureau - AstraZeneca; Ipsen; Roche; Ventana Medical Systems
Research Funding - Ventana Medical Systems (Inst)
Patents, Royalties, Other Intellectual Property - patente pending on indels as a biomarkersin CPI response molecular profiling in RCC
Travel, Accommodations, Expenses - Ventana Medical Systems
 
Nigel Smith
No Relationships to Disclose
 
Alexandra Clipson
No Relationships to Disclose
 
Harry Clarke
No Relationships to Disclose
 
Noel Kelso
No Relationships to Disclose
 
Jackie Mitchell
No Relationships to Disclose
 
Chris Sutton
No Relationships to Disclose
 
Gema Sylvestre
No Relationships to Disclose
 
Paul D. Nathan
Consulting or Advisory Role - 4SC; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Immunocore; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck; MSD; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
James Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kymab; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Secarna; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kymab; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Secarna; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Merck Serono; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
 
Philippa Gail Corrie
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Microbiotica; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Halozyme (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Elizabeth Ruth Plummer
Honoraria - Amgen (I); AstraZeneca/MedImmune; Bristol-Myers Squibb; Novartis Pharmaceuticals UK Ltd.; Pfizer (I); Tesaro
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; Clovis Oncology; CV6 Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Karus Therapeutics; Novartis; Octimet; Pierre Fabre; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
 
Richard Marais
Consulting or Advisory Role - Pfizer
Patents, Royalties, Other Intellectual Property - possible commercialisation of work not yet confirmed
 
Caroline Dive
Honoraria - AstraZeneca; Biocartis; Merck KGaA
Consulting or Advisory Role - AstraZeneca; Biocartis; Merck KGaA
Research Funding - Amgen; Angle; Astex Pharmaceuticals; AstraZeneca; Bayer; BIOVEN; Boehringer Ingelheim; Bristol-Myers Squibb; Carrick Therapeutics; Celgene; Clearbridge Biomedics; GlaxoSmithKline; Menarini; Merck KGaA; Novartis; Roche; Taiho Oncology; Thermofisher Scientific Biomarkers
 
Paul Lorigan
Honoraria - Amgen; BMS; Merck; MSD; NeraCare GmbH; Novartis; Oncology Education; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Research Funding - BMS
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme